IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1721
Positioning
Market Dominance
Manufacturing
Medical Equipment
$511M
James C. Clemmer
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$ANGO ANGIODYNAMICS INC | 52 | 60 | 50 | 46 | - | - | -18.4% | -12.0% | 55.1% | -12.7% | -10.8% | 17.7% | 0.0% | 53.0x | $511M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
ANGIODYNAMICS INC (ANGO) receives a "Hold" rating with a composite score of 51.8/100. It ranks #1721 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
James C. Clemmer
Chief Executive Officer
Labor Force
760
60
46
71
Audit Verdict: Average governance indicators based on financial metrics.
No recent insider transactions available for ANGO
In-line with peers — no strong momentum signal
Fair valuation relative to peers
High profitability & efficiency — strong quality floor supports entry
Low volatility — smoother ride and historically better risk-adjusted returns
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for ANGO.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 60 | 57 | +3NEUTRAL |
| MOMENTUM | 46 | 29 | +17ALPHA |
| VALUATION | 50 | 29 | +21ALPHA |
| INVESTMENT | 46 | 85 | -39DRAG |
| STABILITY | 71 | 66 | +5NEUTRAL |
| SHORT INT | 46 | 42 | +4NEUTRAL |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -18.4% (sector -2.5%)
GM 55% vs sector 43%, OM -13% vs sector 1%
Capital turnover N/A, R&D intensity 9.1%
Rev growth 18%, 11yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our model assigns ANGIODYNAMICS INC a Hold rating, with a composite score of 51.8/100 and 3 out of 5 stars. Ranked #1721 of 7,333 stocks, ANGO presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
With a quality score of 60/100, ANGO shows adequate but unremarkable business quality. The company reports a return on equity of -18.4% (sector avg: -2.5%), gross margins of 55.1% (sector avg: 42.5%), net margins of -10.8% (sector avg: -0.2%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
ANGO's value score of 50/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/B ratio of 2.62x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
With an investment score of 46/100, ANGO exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of 17.7% vs. a sector average of 5.9% and a return on assets of -12.0% (sector: -0.1%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
ANGO is currently showing below-average momentum at 46/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 17.7% year-over-year, while a beta of 1.00 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
ANGO shows good financial stability with a score of 71/100. Key stability metrics include a beta of 1.00 and a debt-to-equity ratio of 53.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
The short interest score of 46/100 for ANGO suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 53.00x), small-cap liquidity risk. With a $511M market cap (small-cap), ANGIODYNAMICS INC may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
ANGIODYNAMICS INC is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1721 of 7,333 overall (77th percentile). Key comparisons include ROE of -18.4% trailing the -2.5% sector median and operating margins of -12.7% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ANGO currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Momentum (46) is the limiting factor — improvement here would lift the composite score most.
ROE 641% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 30% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 1086% BELOW SECTOR MEDIAN
AUDIT DATA AS OF NOV 30, 2025 (Q3 FY2025)
We rate ANGIODYNAMICS INC (ANGO) as a Hold with a composite score of 51.8/100 at a current price of $11.43. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling for existing holders. Our factors are split, and the overall profile suggests patience is warranted.
The rating is primarily driven by strength in stability (71th percentile) and quality (60th percentile), which together account for the majority of the composite score. All factors score above the 40th percentile, indicating no material weakness in the quantitative profile. We assign a No Moat rating (31/100), High uncertainty, and Poor capital allocation.
Key items to watch: the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
ANGIODYNAMICS INC holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 51.8/100 places it at rank #1721 in our full 7,333-stock universe. At $511M in market capitalization, ANGIODYNAMICS INC is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 18%, though momentum at the 46th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 55% (+12.6pp vs sector) narrow to operating margins of -13% (-14.0pp vs sector) and net margins of -10.8%, yielding a gross-to-net conversion rate of -20%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $11.43, ANGIODYNAMICS INC is trading near fair value based on current fundamentals. Our value factor score of 50/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at P/B of 2.6x, P/S of 1.5x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 55% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Revenue growth of 18% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
Thin net margins of -10.8% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a High uncertainty rating to ANGIODYNAMICS INC. Key risk factors include current negative profitability (net margin -10.8%), the combination of leverage (53% D/E) and thin margins (-10.8% net) amplifies downside risk. The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -10.8%); the combination of leverage (53% D/E) and thin margins (-10.8% net) amplifies downside risk. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 71th percentile and quality factor at the 60th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 55% provide a buffer against cost pressures; above-average stability (71th percentile) suggests predictable business dynamics. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate ANGIODYNAMICS INC's capital allocation as Poor. Key concerns include low returns on equity (-18.4%), negative profitability, weak asset returns (ROA -12.0%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — ANGIODYNAMICS INC significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, ANGIODYNAMICS INC receives a Hold rating with a composite score of 51.8/100 (rank #1721 of 7,333). Our quantitative framework assigns a No Moat (31/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 54/100.
Our analysis supports a neutral stance on ANGIODYNAMICS INC. While the quantitative profile is not weak enough to warrant selling, it lacks the multi-factor strength required for a buy recommendation. Existing holders should maintain positions and monitor for catalysts — either fundamental improvement or valuation compression — that would shift the risk-reward balance.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign ANGIODYNAMICS INC a meaningful economic moat, scoring 31/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 12/20.
The strongest moat sources are margin superiority (12/20) and financial resilience (8.7/20). GM 55% vs sector 43%, OM -13% vs sector 1%. Interest coverage N/A. These pillars form the core of ANGIODYNAMICS INC's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (0.6/20) and reinvestment efficiency (3.2/20). ROE proxy -18.4% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect ANGIODYNAMICS INC's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 55% providing a solid profitability foundation, robust top-line growth of 18% expanding the revenue base. The margin cascade from 55% gross to -13% operating to -10.8% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that the profit engine is high-quality and likely sustainable, with the quality factor at the 60th percentile.
The margin profile shows gross margins of 55%, operating margins of -13%, net margins of -10.8%. Return metrics include ROE of -18.4% and ROA of -12.0%. Relative to the Manufacturing sector, gross margins are 12.6 percentage points above the sector median of 43%, and ROE of -18.4% compares to a sector median of -2.5%.
The balance sheet reflects moderate leverage with D/E of 53%, revenue growth of 18%. The sector median D/E is 0%, putting ANGIODYNAMICS INC at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
LATHAM, N.Y., February 23, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference on Monday, Mar. 9, 2026. The Company's presentation will begin at 1:40 p.m. (ET).
LATHAM, N.Y., February 19, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced expanded European indications for its NanoKnife System to include soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, including in patients with intermediate-risk prostate cancer.
Growing Clinical Evidence and Physician Adoption Broaden NanoKnife IRE Technology as Treatment Option for Major Solid Tumor TypesAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company

Although U.S. stocks closed little changed on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Semtech The Trade: Semtech Corporation (NASDAQ: SMTC) EVP and CFO Mark Lin acquired a total of 1,000 shares an average price of $33.23. To acquire these shares, it cost around $33,232. What’s Happening: On March 28, ...

AngioDynamics shares fell 13.1% despite posting strong Q3 results with revenue of $79.4 million (beating estimates) and better-than-expected earnings. The sell-off was triggered by the unexpected announcement of CEO Jim Clemmer's retirement after 10 years leading the company. While the board has formed a search committee to find a successor and the company raised its 2026 guidance, investor uncertainty about leadership transition overshadowed the positive business fundamentals.
Above 50MA
37.18%
Net New Highs
+51081